ADA(s), anti-drug antibody(ies); AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANCOVA, analysis of covariance; AST, aspartate aminotransferase; CFB, change from baseline; CTX-1, C-terminal telopeptide of type 1 collagen; C­P, Child-Pugh; DXA, dual-energy X-ray absorptiometry; ELF, enhanced liver fibrosis; FGF21; FGF21, fibroblast growth factor-21; FGFR, fibroblast growth factor receptor; GGT, gamma-glutamyltransferase; HDL-C, HDL-cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; HPA, hypothalamic-pituitary-adrenal; HbA1c, hemoglobin A1c; INR, international normalized ratio; IRT, interactive response technology; LDL-C, LDL-cholesterol; LS, least squares; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; NAb, neutralizing antibody; Non-HDL-C, non-HDL-cholesterol; P1NP, procollagen type-I N-terminal propeptide; P3NP, procollagen type III N-terminal propeptide; PAI-1, plasminogen activator inhibitor-1; Pro-C3, N-terminal type III collagen propeptide; TEAE, treatment-emergent adverse event; TIMP-1, tissue inhibitor of metalloproteinase-1; ULN, upper limit of normal; cirrhosis; clinical trial; efruxifermin; histopathology; hs-CRP, high-sensitivity C-reactive protein; liver disease; non-alcoholic steatohepatitis/NASH; nonalcoholic fatty liver disease/NAFLD